Yes, but more importantly changing anything about bisantrene pushes development right back to the start. Instead of being able to build on all the historical data to speed development and approval you have to start again from scratch. This is why we have avoided changing the way bisantrene was prepared and formulated (we have patents on the changes COH made to the formulation).
Even if they were able to overcome our granted patents they would run straight into our orphan drug designation. Even if they were able to somehow get their new formulation all the way through the drug development process, they would find that they couldn’t sell their drug for 7 years because we got to approval first and thus have sales exclusivity. No rational investor is going to put money into developing bisantrene without coming to some agreement with us.
RAC - Charts & Price Action, page-228
- There are more pages in this discussion • 20,772 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
-0.030(1.86%) |
Mkt cap ! $264.5M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.60 | $1.58 | $5.894K | 3.713K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 307 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.66 | 8946 | 1 |
View Market Depth
| Last trade - 11.01am 16/05/2024 (20 minute delay) ? |
| RAC (ASX) Chart |